News

11th January 2010
Crescent will present at the Medtech Investing Forum on the 18th February 2010 in Lausanne.

23rd December 2009
Crescent awarded UK Patent for novel instrument design.

31st January 2009
Stéphane Sallmard appointed as a non-executive director.

London, UK, Jan 31, 2009:
Crescent Diagnostics Ltd (“Crescent”), today announced the appointment of Stéphane Sallmard as a non-executive director. Mr. Sallmard is a seasoned healthcare executive who has held senior positions with General Electric Medical Systems and Acuson Inc. Most recently he was the CEO of Optos Plc. (UK) where he was instrumental in attracting $28M in new funding, growing the company from $1.5M revenues in 2001 to $67M revenues in 2006 and taking it public on the London Stock Exchange in early 2006. Stéphane Sallmard is also Chairman of the Board of Directors of Forth Photonics.

8th June 2007
Crescent Diagnostics announces positive clinical results for its Novel Bone Quality Test, BQT^®
Crescent Diagnostics Ltd today announced the publication of a recent study demonstrating the potential of the Bone Quality Test, BQT^® to diagnose osteoporosis.

Full story >>>

March 8th 2007
Crescent Diagnostics Announces Start of FRAN Clinical Study

Crescent Diagnostics Ltd, a revolutionary developer of the Bone Quality Test, BQT^® announced today the start of the Fracture Risk Assessment Nail Correlation Study, FRAN.

Download the PDF version >>>

October 8th 2006
Crescent Diagnostics profiled in Clinica

Crescent Diagnostics Ltd., a privately held company developing a new test for bone health, was profiled in Clinica today.

Download the PDF version >>>

18th July 2006
Crescent Diagnostics and DeltaNu Ink IP Agreement

July 18th - Limerick, Ireland and Laramie, Wyoming USA: Crescent Diagnostics Ltd. has signed an intellectual property option agreement with DeltaNu LLC. This agreement gives Crescent an exclusive option to develop and market products from intellectual property that was invented at the University of Limerick and the University of Wyoming and is jointly held by Crescent and DeltaNu. The intellectual property describes a novel way to use Raman spectroscopy to diagnose bone health conditions like osteoporosis. The terms of the agreement were not disclosed. "We are very happy to conclude an agreement like this - it formalizes a great working relationship we've had with DeltaNu for the past two years," says Ernest Poku, CEO of Crescent Diagnostics. "The applications for Raman spectroscopy are growing," says Dr. Keith Carron, CEO of DeltaNu, "and DeltaNu is fortunate to partner with a leader like Crescent as it brings this important technology to the market."

13th June 2006
Crescent Diagnostics Secures Venture Capital Financing

Crescent Diagnostics Ltd., a privately held company developing a new test for bone health, today announced the completion of a £550,000 (€800,000) funding round. Seroba BioVentures (Seroba), a Dublin-based specialist life science venture capital firm led the round in conjunction with a number of private investors.

Download the PDF version or read the full story >>>

9th Nov 2005
Crescent Diagnostics Runner-up in Medical Futures Awards 2005

CEO Ernest Poku said "The endorsement that comes from this kind of recognition in the medical community cannot be underestimated. We are confident that we will go on to justify their faith in the technology". Crescent Diagnostics is currently carrying out in-house and contract research on the biomarker with a view to enabling commercial applications in the near future.

10th July 2005
Fingernail test for bone disease
BBC News Website